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Abstract
Introduction: Recently, several genome-wide association studies (GWAS) have identified novel single nucleotide
polymorphisms (SNPs) associated with breast cancer risk. However, most of the studies were conducted among
Caucasians and only one from Chinese.
Methods: In the current study, we first tested whether 15 SNPs identified by previous GWAS were also breast
cancer marker SNPs in this Chinese population. Then, we grouped the marker SNPs, and modeled them with
clinical risk factors, to see the usage of these factors in breast cancer risk assessment. Two methods (risk factors
counting and odds ratio (OR) weighted risk scoring) were used to evaluate the cumulative effects of the five
significant SNPs and two clinical risk factors (age at menarche and age at first live birth).
Results: Five SNPs located at 2q35, 3p24, 6q22, 6q25 and 10q26 were consistently associated with breast cancer
risk in both testing set (878 cases and 900 controls) and validation set (914 cases and 967 controls) samples.
Overall, all of the five SNPs contributed to breast cancer susceptibility in a dominant genetic model (2q35,
rs13387042: adjusted OR = 1.26, P = 0.006; 3q24.1, rs2307032: adjusted OR = 1.24, P = 0.005; 6q22.33, rs2180341:
adjusted OR = 1.22, P = 0.006; 6q25.1, rs2046210: adjusted OR = 1.51, P = 2.40 × 10-8; 10q26.13, rs2981582: adjusted
OR = 1.31, P = 1.96 × 10-4). Risk score analyses (area under the curve (AUC): 0.649, 95% confidence interval (CI):
0.631 to 0.667; sensitivity = 62.60%, specificity = 57.05%) presented better discrimination than that by risk factors
counting (AUC: 0.637, 95% CI: 0.619 to 0.655; sensitivity = 62.16%, specificity = 60.03%) (P < 0.0001). Absolute risk
was then calculated by the modified Gail model and an AUC of 0.658 (95% CI = 0.640 to 0.676) (sensitivity =
61.98%, specificity = 60.26%) was obtained for the combination of five marker SNPs, age at menarche and age at
first live birth.
Conclusions: This study shows that five GWAS identified variants were also consistently validated in this Chinese
population and combining these genetic variants with other risk factors can improve the risk predictive ability of
breast cancer. However, more breast cancer associated risk variants should be incorporated to optimize the risk
assessment.
Introduction
Breast cancer is one of the most common cancers
among women worldwide [1]. Although life/environ-
ment related factors are implicated in breast carcinogen-
esis, it is a complex polygenic disorder in which genetic
makeup also plays an important role [2,3]. In the past
decades, high-penetrance genes (for example, BRCA1,
BRCA2, PTEN and TP53) have been identified to be
associated with familiar breast cancer [4]. However,
these genes account for less than 5% of overall breast
cancer patients and most of the risk is likely to be attri-
butable to more low-penetrance genetic variants [5-7].
Recently, several genome-wide association studies
(GWAS) reported many novel breast cancer predispos-
ing single nucleotide polymorphisms (SNPs) [8-14].
However, most of the studies were conducted among
Caucasians [8-13] and only one among Chinese [14],
and whether these genetic variants are applicable marker
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SNPs in Asian women is unclear. Furthermore, evalua-
tion of a risk-predicting model is an important topic in
genetic studies of human diseases, including breast can-
cer. An effective risk-predicting model can assist physi-
cians in disease prevention, diagnosis, prognosis and
treatment [15]. For the harvest of GWAS on breast can-
cer, many studies combined the genetic markers and
other traditional risk factors together to evaluate the
risk-predicting model of breast cancer [16-22]. However,
most of the breast cancer risk model effects are unsatis-
fied and only one related study was available in Chinese
women [17].
In the current study, a two-stage case-control study of
1,792 breast cancer cases and 1,867 cancer-free controls
was conducted among Chinese women to replicate 15
selected SNPs identified from previous GWAS. Then,
risk models were constructed and absolute risk was cal-
culated to evaluate the combined effects of the signifi-
cant SNPs and clinical risk factors.
Materials and methods
Study subjects
This study was approved by the institutional review
board of Nanjing Medical University. The hospital-based
case-control study included 1,792 breast cancer cases
and 1,867 cancer-free controls, and the detail process of
subjects recruitment was described previously [23-25].
In brief, incident breast cancer patients were consecu-
tively recruited from the First Affiliated Hospital of
Nanjing Medical University, the Cancer Hospital of
Jiangsu Province and the Gulou Hospital, Nanjing,
China, between January 2004 and April 2010. Exclusion
criteria included reported previous cancer history,
metastasized cancer from other organs, and previous
radiotherapy or chemotherapy. All breast cancer cases
were newly-diagnosed and histopathologically con-
firmed, without restrictions of age or histological types.
Cancer-free control women, frequency-matched to the
cases on age (± 5 years) and residential area (urban or
rural), were randomly selected from a cohort of more
than 30,000 participants in a community-based screen-
ing program for non-infectious diseases conducted in
the same region. All participants were ethnic Han Chi-
nese women. Of the eligible participants, 878 cases and
900 controls were randomly assigned to form the testing
set, and the remaining 914 cases and 967 controls
formed the validation set.
After providing informed consent, each woman was
personally interviewed face-to-face by trained inter-
viewers using a pre-tested questionnaire to obtain infor-
mation on demographic data, menstrual and
reproductive history, and environmental exposure his-
tory. After the interview, each subject provided 5 ml of
venous blood. The estrogen receptor (ER) and
progesterone receptor (PR) status of breast cancer was
determined by immunohistochemistry examinations
which were obtained from the medical records of the
hospitals.
SNP selection and genotyping
The SNP selection procedure followed three criteria: (a)
reported marker SNP in previous GWAS (last search in
November 2009); (b) minor allele frequency (MAF) ≥
0.05 in Chinese Han Beijing (CHB) based on the HapMap
database (phase II, released 24 in November 2008); (c)
only SNPs with low linkage disequilibrium (LD) were
included (r2 < 0.8) if multiple SNPs can be found at the
same region. Overall, 15 SNPs (11 regions of 2q35, 3p24,
5p11, 5p12, 6q22, 6q25, 8q24, 10q26, 11p15, 16q12 and
17q23; Table 1) were selected and genotyped by using
the middle-throughput TaqMan OpenArray Genotyping
Platform (Applied Biosystems Inc., Carlsbad, CA, USA)
for testing set samples (878 cases and 900 controls) and
by TaqMan Assays on ABI PRISM 7900 HT Platform
(Applied Biosystems Inc.) for validation set samples (914
cases and 967 controls). For OpenArray Assays, normal-
ized human DNA samples were loaded and amplified on
customized arrays following the manufacturer’s instruc-
tions. Each 48-sample array chip contained two NTCs
(no template controls). For TaqMan Assays, approxi-
mately equal numbers of case and control samples were
assayed in each 384-well plate. Two blank controls in
each plate were used for quality control and 96 duplicates
were randomly selected to repeat for the two platforms,
and the results were more than 97% concordant.
Statistical analyses
Differences between breast cancer cases and controls in
demographic characteristics, risk factors and frequencies
of SNPs were evaluated by Fisher’s exact tests (for cate-
gorical variables) or Student t-test or t’-test (equal var-
iances not assumed) (for continuous variables). Hardy-
Weinberg equilibrium was evaluated by exact test
among the controls [26].
As shown in Additional file 1, three steps were per-
formed to assess the breast cancer risk model. (1) SNPs
screening. Following a two-stage strategy, associations
between SNPs and risk of breast cancer were estimated
by computing odds ratios (ORs) and their 95% confi-
dence intervals (CIs). (2) Risk model construction. For
the model parsimony, only genetic or clinical risk factors
that were independently associated with breast cancer
were included. Both OR (odds ratio) and AR (absolute
risk) were taken as indicators to evaluate the risk model.
For the OR-based risk model, two different methods
were used. One method treated each risk allele/factor
equally and combined them based on the counts of risk
alleles/factors. Another method assessed the effects of
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Table 1 Association of breast cancer risk with 15 SNPs selected from previous GWAS study in the Testing Set.
SNP Chr.
(Cytoband)
Position Associated genes GWAS study Allelesa Call
Rate
(%)
P b MAFc MAFd Case (%) Control (%) P e




G > A 98.65 0.41 0.11 0.12 1.39/25.87/72.74 1.01/21.08/77.91 0.039
rs4973768 3p24.1 27391017 SLC4A7 Ahmed, 2009 (8) C > T 97.58 0.91 0.17 0.19 3.05/35.05/61.90 3.63/31.52/64.85 0.265
rs2307032 3p24.1 27407999 SLC4A7 Ahmed, 2009 (8) C > T 97.92 0.08 0.41 0.40 18.58/50.64/30.78 17.61/45.23/37.16 0.017
rs16886165 5p11.2 56058840 MAP3K1 Thomas, 2009 (13) T > G 96.34 0.65 0.31 0.34 12.10/46.98/40.93 11.49/45.98/42.53 0.781
rs889312 5q11.2 56067641 MAP3K1 Easton, 2007 (9) C > A 98.31 0.23 0.50 0.48 21.55/50.41/28.04 22.03/52.09/25.88 0.595
rs4415084 5p12 44698272 Unknown Stacey, 2008 (12)
Thomas,2009 (13)
A > G 96.12 0.03 0.46 0.43 19.95/44.56/35.84 20.41/45.64/33.94 0.798
rs10941679 5p12 44742255 MRPS30 Stacey, 2008 (12)
Thomas,2009 (13)
G > A 97.19 0.95 0.57 0.50 24.23/49.29/26.48 24.83/50.23/24.94 0.768
rs2180341 6q22.33 127642323 ECHDC1, RNF146 Gold, 2008 (10) A > G 97.30 0.49 0.22 0.26 6.35/43.88/49.76 7.50/37.95/54.55 0.040
rs2046210 6q25.1 151990059 ESR1, C6orf97 Zheng, 2009 (14) G > A 98.48 0.50 0.35 0.34 18.35/47.97/33.68 12.36/44.16/43.48 1.26 × 10-5
rs13281615 8q24.21 128424800 Unknown Easton, 2007 (9) A > G 97.98 0.59 0.57 0.49 23.56/52.40/24.03 24.63/49.04/26.32 0.353
rs1562430 8q24.21 128457034 Unknown Thomas 2009 (13) T > C 98.82 0.11 0.20 0.18 2.75/27.38/69.87 2.49/31.33/66.18 0.191
rs2981582 10q26.13 123342307 FGFR2 Easton, 2007 (9) C > T 99.44 0.94 0.33 0.31 12.61/45.87/41.51 9.82/43.3/46.88 0.037
rs3817198 11p15.5 1865582 LSP1 Easton, 2007 (9) T > C 98.82 0.88 0.09 0.12 2.41/23.79/73.79 1.58/21.53/76.89 0.213
rs12443621 16q12.1 51105538 TNRC9 Easton, 2007 (9) G > A 99.10 0.34 0.39 0.45 18.23/48.17/33.60 19.10/51.12/29.78 0.227
rs6504950 17q23.2 50411470 COX11 Ahmed, 2009 (8) G > A 98.71 0.84 0.10 0.09 0.35/14.14/85.52 0.78/15.92/83.30 0.264
a Major > Minor; b P-values for Hardy-Weinberg equilibrium(HWE) in the controls by exact test; c Minor Allele Frequency (MAF) of Chinese Han population from Beijing (CHB) based on the International HapMap














the SNPs and risk factors using a risk score analysis
with a linear combination of the SNP genotypes or risk
factors weighted by their individual OR (The log odds at
each SNP locus was additive in the number of minor
alleles, and the log odds for the entire model was addi-
tive across SNPs and other risk factors). Then the risk
score was classified into four groups by its quartiles in
controls. AR is the risk of developing a disease over a
time-period. In our paper, the AR for each woman was
estimated by a modified Gail model [16,27]. This
method is described as a multiplicative model used to
derive genotype relative risk from the allelic OR. The
allelic OR for each SNP was obtained assuming an addi-
tive genetic model by logistic regression analysis. For
each of the three genotypes at each SNP, the genotype
relative risk was converted to the risk relative to the
population. The overall risk relative to the population
was derived by combining the risks relative to the popu-
lation of all SNPs as well as the two clinical risk factors
(age at menarche and age at first live birth) of the indi-
vidual by multiplication. Finally, the AR for each woman
was obtained based on the overall risk relative to the
population, calibrated by the incidence rate of breast
cancer for women (aged 20 to 85 years), and the mortal-
ity rate for all causes except breast cancer from the
Shanghai registration system, China [28]. (3) Risk model
discrimination. The model performance was evaluated
by receiver-operator characteristic (ROC) curves and the
area under the curve (AUC) to classify the breast cancer
cases and controls. The difference of AUCs was tested
by a non-parametric approach developed by DeLong ER
et al. [29]. Furthermore, for the absolute risk-based risk
models, we used the 10-fold cross-validation method to
check the reliability of the models. All of the statistical
analyses were two-sided and performed with Statistical
Analysis System software (9.1.3; SAS Institute, Cary,
NC, USA) and Stata (9.2; StataCorp LP, Lakeway Drive
College Station, TX, USA), unless indicated otherwise.
Results
A total of 1,792 breast cancer cases and 1,867 cancer-
free controls were included in the final analysis, and the
characteristics of these subjects were summarized in
Table 2. Age at menarche (P < 0.001) and age at first
Table 2 Distribution of demographic characteristics and known breast cancer risk factors for cases and controls
included in the study














Age, yr (Mean ± SD) 51.29 ± 11.38 51.47 ± 11.67 50.11 ± 11.36 48.64 ± 12.28 50.69 ± 11.38 50.01 ± 12.07 0.08
Age group, yr (%) 0.06
< 50 425 (48.41) 463 (51.44) 467 (51.09) 526 (54.40) 896 (49.78) 989 (52.97)
≥ 50 453 (51.59) 437 (48.56) 447 (48.91) 441 (45.60) 900 (50.22) 878 (47.03)
Age at menarche, yr (Mean ± SD) 15.26 ± 1.83 15.85 ± 1.89 15.19 ± 1.94 16.23 ± 1.81 15.22 ± 1.89 16.05 ± 1.86 < 0.001
Age at menarche group, yr (%) < 0.001
< 15 (Early menarche) 331 (38.40) 227 (25.33) 357 (39.98) 169 (17.57) 688 (39.20) 396 (21.31)
15 to 17 (Normal menarche) 325 (37.70) 352 (39.29) 333 (37.29) 376 (39.09) 658 (37.49) 728 (39.18)
≥ 17 (Late menarche) 206 (23.90) 317 (35.38) 203 (22.73) 417 (43.35) 409 (23.30) 734 (39.50)
Age at first live birth, yr (Mean ± SD) 25.62 ± 3.39 24.90 ± 3.35 25.51 ± 3.06 24.17 ± 2.51 25.56 ± 3.22 24.52 ± 2.99 < 0.001d
Age at first live birth group, yr (%)a < 0.001
< 25 (Early birth) 305 (34.74) 398 (44.27) 312 (34.36) 527 (54.67) 617 (34.55) 925 (49.65)
≥ 25a (Late birth) 573 (65.26) 501 (55.73) 596 (65.64) 437 (45.33) 1,169 (65.45) 938 (50.35)
Age at menopause, yr. (Mean ± SD)b 49.15 ± 4.09 48.90 ± 4.43 48.71 ± 4.63 49.42 ± 4.04 48.93 ± 4.37 49.16 ± 4.25 0.27
Menopausal status (%)b 0.02
Premenopausal 416 (47.38) 437 (48.56) 434 (47.48) 529 (54.71) 850 (47.43) 966 (51.74)
Postmenopausal 444 (50.57) 448 (49.78) 463 (50.66) 428 (44.26) 907 (50.61) 876 (46.92)
Estrogen receptor (ER) (%)c
Positive 369 (42.03) 434 (47.48) 803 (44.81)
Negative 321 (36.56) 322 (35.23) 643 (35.88)
Progesterone receptor (PR) (%)c
Positive 396 (45.10) 414 (45.30) 810 (45.20)
Negative 294 (33.49) 340 (37.20) 634 (35.38)
a 10 women (0.27%) without live birth were grouped as “later birth”. b Menopause information was available: 907 (51.62%) postmenopausal breast cancer cases
and 876 (47.56%) postmenopausal controls. c 1,446 (80.69%) ER status and 1,444 (80.58%) PR status was available in cases. d P-value calculated by t’ test for the
unequal variances between groups.
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live birth (P < 0.001) were consistently, differentially dis-
tributed between the cases and the controls in all sam-
ples. Among 1,437 breast cancer cases with known ER
and PR status, 662 (46.07%) were both ER and PR posi-
tive, and 498 (34.66%) were both negative.
The results of the selected 15 SNPs and the breast
cancer risk in testing set samples were presented in
Table 1. The call rates of the 15 SNPs were all above
95% and the MAF in the controls were all above 0.05.
Five SNPs at 2q35, 3p24, 6q22, 6q25 and 10q26 were
significantly associated with breast cancer risk (2q35:
rs13387042, P = 0.039; 3p21.4: rs2307032, P = 0.017;
6q22.33: rs2180341, P = 0.040; 6q25.1: rs2046210, P =
1.26 × 10-5; 10q26.13: rs2981582, P = 0.037). Therefore,
these five SNPs were included in the further validation
analyses.
The call rates of the five SNPs in the validation stage
were all above 95% (Table 3). Consistent associations
were observed for the five SNPs, with significant or bor-
derline significant P-values. Overall, after adjustment for
age, age at menarche, menopausal status and age at first
live birth, the five SNPs showed significant associations
with breast cancer susceptibility (dominant genetic
model: 2q35, rs13387042: OR = 1.26, 95% CI = 1.07 to
1.49; 3q24.1, rs2307032: OR = 1.24, 95% CI = 1.07 to
1.44; 6q22.33, rs2180341: OR = 1.22, 95% CI = 1.06 to
1.40; 6q25.1, rs2046210: OR = 1.51, 95% CI = 1.31 to
1.75; 10q26.13, rs2981582: OR = 1.31, 95% CI = 1.14 to
1.50).
The cumulative effects of the five SNPs and the two
risk factors (age at menarche and age at first live birth)
on breast cancer risk were examined by two methods
(Table 4). One method was based on the counting of
risk alleles/factors. Women carrying six or more risk
alleles of the five SNPs (5.75% of case patients and
3.23% of control subjects) had a nearly three-fold
increased risk for developing breast cancer compared
with those carrying less than one of the risk alleles
(11.08% of case subjects and 16.70% of control subjects).
When taking age at menarche and age at first live birth
into consideration, the top group (having more than
seven risk alleles/factors) had a 5.61-fold increased risk
compared to the reference group (adjusted OR = 5.61,
95% CI = 4.16 to 7.56). Another method was based on
the risk score calculated with a linear combination of
the SNP alleles or risk factors weighted by the individual
odds ratio and then classified into four groups by the
quartiles. Subjects with the upper quartile risk score
were associated with a 91% increased breast cancer risk
compared to those having the low quartile score
(adjusted OR = 1.91, 95% CI = 1.56 to 2.35, P for trend:
5.60 × 10-10). Similarly, a 4.73-fold increased risk was
illustrated when taking age at menarche and age at first
live birth into consideration (adjusted OR = 4.73, 95%
CI = 3.80 to 5.88, P for trend: 2.27 × 10-47). We then
assessed the performance of the two risk prediction
methods in discriminating cases and controls by ROC
curves analyses. The AUC for the risk score analysis
(0.649, 95% CI: 0.631 to 0.667; sensitivity = 62.60%, spe-
cificity = 57.05%, Figure 1) was significantly higher than
that by the risk factors counting method (AUC: 0.637,
95% CI: 0.619 to 0.655; sensitivity = 62.16%, specificity =
60.03%, Figure 2) (P < 0.0001).
Absolute risk was also calculated to evaluate the com-
bined effects of the five SNPs and the two risk factors
by a modified Gail model and a 65-year absolute risk for
breast cancer among women aged 20 to 85 years was
estimated for each subject. From Table 5, a clear trend
was observed that more subjects were grouped as high
risk along with the increased numbers of risk alleles/fac-
tors. However, the variation of absolute risk distribution
increased with increasing numbers of factors used in the
risk-predicting model. Compared to a uniform 65-year
cumulative risk 0.07 as carrying four risk factors (chosen
by the largest proportion in controls: 22.01%, Table 5)
for breast cancer in the population, a wide spectrum of
absolute risk estimates was found using these five mar-
kers and the two clinical risk factors (Figure 3). At a
cutoff of 0.14 (two-fold of the population median risk)
or 0.21 (three-fold of the population median risk),
26.57% or 10.43% of women were grouped as high risk,
respectively. We also used the ROC curve analysis to
evaluate the performance of absolute risk to classify the
cases and controls. As shown in Figure 4, we obtained
an AUC of 0.658 (95% CI: 0.640 to 0.676) (sensitivity =
61.98%, specificity = 60.26%) for five SNPs plus two risk
factors. Based on the cross-validation, similar results for
AUCs were obtained (0.572 (five SNPs only), 0.644 (two
risk factors only) and 0.660 (five SNPs plus two risk fac-
tors)), which suggests a relative reliability of the models.
The stratified analyses by ER or PR status of the five
SNPs were summarized in Additional file 2. However,
no significant heterogeneity was observed for the effect
of each SNP by different ER or PR subgroups. Further
stratified analysis was conducted on the cumulative
effects of the five SNPs (coded 0 to 2 risk alleles as 0
and more than 3 risk alleles as 1) and found no hetero-
geneity between subgroups (Additional file 3).
Discussion
In our study involving 1,792 breast cancer cases and
1,867 cancer-free controls, 5 of the 15 variants, identi-
fied in previous GWAS studies [8-14], were consistently
associated with breast cancer risk in this Chinese popu-
lation. Risk assessment models and absolute risk calcula-
tions combining the five SNPs and two clinical risk
factors indicated the small effects of these markers in
discriminating cases and controls. Overall, the results
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Table 3 Association of SNPs with breast cancer risk in both testing and validation sets






P a Adjusted OR
(95% CI)b












GG 627 (72.74) 695 (77.91) 712 (78.33) 773 (80.60) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
GA 223 (25.87) 188 (21.08) 181 (19.91) 178 (18.56) 1.29 (1.03 to 1.63) 0.030 1.21 (0.93 to 1.56) 0.155 1.23 (1.04 to 1.46) 0.018
AA 12 (1.39) 9 (1.01) 16 (1.76) 8 (0.83) 1.46 (0.60 to 3.54) 0.407 2.56 (1.03 to 6.38) 0.044 1.95 (1.04 to 3.66) 0.037
GA/AA 235 (27.26) 197 (22.09) 197 (21.67) 186 (19.40) 1.30 (1.04 to 1.63) 0.023 1.27 (0.99 to 1.63) 0.064 1.26 (1.07 to 1.49) 0.006
A allelic trend (Additive model) 1.30 (1.05 to 1.62) 0.017 1.21 (0.97 to 1.51) 0.085 1.25 (1.07 to 1.46) 0.004
3q24.1: rs2307032
CC 265 (30.78) 327 (37.16) 288 (31.58) 326 (34.42) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
CT 436 (50.64) 398 (45.23) 429 (47.04) 464 (49.00) 1.31 (1.05 to 1.63) 0.016 1.09 (0.87 to 1.37) 0.459 1.20 (1.02 to 1.40) 0.027
TT 160 (18.58) 155 (17.61) 195 (21.38) 157 (16.58) 1.27 (0.95 to 1.69) 0.105 1.43 (1.06 to 1.91) 0.018 1.36 (1.11 to 1.66) 0.003
CT/TT 596 (69.22) 553 (62.84) 624 (68.42) 621 (65.58) 1.30 (1.06 to 1.60) 0.014 1.18 (0.95 to 1.46) 0.138 1.24 (1.07 to 1.44) 0.005
T allelic trend (Additive model) 1.11 (0.97 to 1.27) 0.122 1.17 (1.02 to 1.34) 0.025 1.14 (1.04 to 1.26) 0.006
6q22.33: rs2180341
AA 423 (49.76) 480 (54.55) 479 (52.64) 541 (56.53) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
AG 373 (43.88) 334 (37.95) 380 (41.76) 350 (36.57) 1.29 (1.05 to 1.59) 0.016 1.26 (1.02 to 1.56) 0.033 1.28 (1.10 to 1.48) 0.001
GG 54 (6.35) 66 (7.50) 51 (5.60) 66 (6.90) 0.96 (0.64 to 1.43) 0.847 0.87 (0.57 to 1.32) 0.505 0.93 (0.70 to 1.24) 0.614
AG/GG 427 (50.24) 400 (45.45) 431 (47.36) 416 (43.47) 1.24 (1.01 to 1.51) 0.036 1.20 (0.97 to 1.47) 0.086 1.22 (1.06 to 1.40) 0.006
G allelic trend (Additive model) 1.10 (0.94 to 1.29) 0.222 1.06 (0.90 to 1.24) 0.496 1.08 (0.97 to 1.20) 0.174
6q25.1: rs2046210
GG 290 (33.68) 387 (43.48) 292 (32.19) 380 (39.58) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
GA 413 (47.97) 393 (44.16) 460 (50.72) 443 (46.15) 1.46 (1.17 to 1.81) 6.31 × 10to 4 1.38 (1.10 to 1.73) 4.81 × 10-3 1.43 (1.23 to 1.67) 5.12 × 10-6
AA 158 (18.35) 110 (12.36) 155 (17.09) 137 (14.27) 2.05 (1.52 to 2.76) 2.95 × 10-6 1.54 (1.13 to 2.09) 5.76 × 10-3 1.79 (1.45 to 2.22) 7.13 × 10-8
GA/AA 571 (66.32) 503 (56.52) 615 (67.81) 580 (60.42) 1.59 (1.29 to 1.94) 8.52 × 10-6 1.42 (1.15 to 1.76) 1.27 × 10-3 1.51 (1.31 to 1.75) 2.40 × 10-8
A allelic trend (Additive model) 1.41 (1.22 to 1.62) 1.54E-06 1.24 (1.08 to 1.43) 2.27E-03 1.33 (1.20 to 1.46) 1.92E-08
10q26.13: rs2981582
CC 362 (41.51) 420 (46.88) 370 (41.29) 464 (48.95) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
CT 400 (45.87) 388 (43.30) 420 (46.88) 408 (43.04) 1.25 (1.01 to 1.53) 3.85 × 10-2 1.20 (0.97 to 1.49) 9.84 × 10-2 1.24 (1.07 to 1.44) 4.40 × 10-3
TT 110 (12.61) 88 (9.82) 106 (11.83) 76 (8.02) 1.49 (1.07 to 2.08) 1.76 × 10-2 1.82 (1.27 to 2.62) 1.19 × 10-3 1.65 (1.29 to 2.10) 5.75 × 10-5
CT/TT 510 (58.49) 476 (53.13) 526 (58.71) 484 (51.05) 1.29 (1.06 to 1.57) 1.15 × 10-2 1.29 (1.05 to 1.59) 9.84 × 10-2 1.31 (1.14 to 1.50) 1.96 × 10-4
T allelic trend (Additive model) 1.23 (1.07 to 1.42) 0.005 1.30 (1.12-1.51) 0.0005 1.27 (1.15 to 1.41) 4.89E-06














provide further evidence and utility for GWAS identified
SNPs in relation to breast cancer risk assessment in
Chinese women.
We summarized associations of the 15 SNPs of
breast cancer identified by previous GWAS studies and
following replication studies (Additional file 4). SNP
rs13387042 at 2q35 was identified as a breast cancer
susceptibility SNP in two GWAS conducted among
Europeans [12,13]. Significant associations were also
observed in most of the later studies on Europeans
Figure 1 The area under curves (AUCs) for breast cancer risk-
predicting models calculated by risk score method.
Figure 2 The area under curves (AUCs) for breast cancer risk-
predicting models calculated by risk counting method.
Table 4 Cumulative effects of associated SNPs and clinical risk factors on the risk of breast cancer in all samples
Risk models TS + VS sets Adjusted ORc
(95% CI)
P c P for trendc
Cases (%) Controls (%)
Counts of risk allelesa
0 to 1 187 (11.08) 295 (16.70) 1.00 (ref.)
2 327 (19.37) 408 (23.10) 1.25 (0.98 to 1.60) 7.04E-02
3 472 (27.96) 503 (28.48) 1.48 (1.18 to 1.87) 8.04E-04
4 404 (23.93) 351 (19.88) 1.85 (1.45 to 2.35) 6.03E-07
5 201 (11.91) 152 (8.61) 2.09 (1.56 to 2.79) 6.76E-07
≥ 6 97 (5.75) 57 (3.23) 2.67 (1.81 to 3.93) 6.40E-07 2.27E-12
Counts of risk factorsb
0 to 2 109 (6.61) 277 (15.79) 1.00 (ref.)
3 203 (12.31) 344 (19.61) 1.54 (1.16 to 2.04) 3.08E-03
4 335 (20.32) 386 (22.01) 2.28 (1.75 to 2.99) 1.54E-09
5 346 (20.98) 377 (21.49) 2.47 (1.89 to 3.23) 4.11E-11
6 338 (20.50) 219 (12.49) 4.19 (3.15 to 5.56) 4.07E-23
≥ 7 318 (19.28) 151 (8.61) 5.61 (4.16 to 7.56) 1.03E-29 3.76E-40
Genetic risk scorea
0 (< Q25) 349 (20.68) 487 (27.58) 1.00 (ref.)
1(Q25 to Q50) 406 (24.05) 499 (28.26) 1.21 (0.99 to 1.48) 6.96E-02
2 (Q50 to Q75) 436 (25.83) 405 (22.93) 1.57 (1.28 to 1.93) 1.74E-05
3 (≥ Q75) 497 (29.44) 375 (21.23) 1.91 (1.56 to 2.35) 5.60E-10 2.02E-11
Genetic & clinical risk scoreb
0 (< Q25) 167 (10.13) 437 (24.91) 1.00 (ref.)
1 (Q25 to Q50) 332 (20.13) 442 (25.20) 2.01 (1.60 to 2.53) 2.68E-09
2 (Q50 to Q75) 406 (24.62) 438 (24.97) 2.55 (2.03 to 3.20) 6.66E-16
3 (≥ Q75) 744 (45.12) 437 (24.91) 4.73 (3.80 to 5.88) 2.38E-44 2.27E-47
a Based on the five SNPs; b Based on five SNPs and two risk factors; c Adjust for age, age at menarche, menopausal status and age at first live birth where was
appropriate.
Dai et al. Breast Cancer Research 2012, 14:R17
http://breast-cancer-research.com/content/14/1/R17
Page 7 of 12
and African American women [30-36] except for one
reported by Stevens KN et al. [37]. However, the
results were conflicting in Asian populations
[12,17,38,39]. For 3p24, Ahmed et al. reported marker
SNPs rs4973768 and rs1357245 in a four-stage GWAS
study, and then located the strongest marker
rs2307032 in this region [8]. Following replication stu-
dies for 3p24 region also presented consistent results
among European [34-37] and Asian [38,40], including
our study. SNP rs2180341 at 6q21.33 was originally
Table 5 Absolute risk estimated in all samples
Groups Case (%) Controls (%) Relative risk Absolute risk
Median (SD) Min to Max Median (SD) Min to Max
Counts of risk allelesa
0 to 1 187 (11.08) 295 (16.70) 0.51 (0.05) 0.45 to 0.59 0.03 (0.003) 0.03 to 0.03
2 327 (19.37) 408 (23.10) 0.65 (0.06) 0.53 to 0.77 0.04 (0.003) 0.03 to 0.04
3 472 (27.96) 503 (28.48) 0.81 (0.08) 0.61 to 0.97 0.05 (0.005) 0.04 to 0.06
4 404 (23.93) 351 (19.88) 0.96 (0.11) 0.69 to 1.23 0.06 (0.006) 0.04 to 0.07
5 201 (11.91) 152 (8.61) 1.16 (0.12) 0.87 to 1.53 0.07 (0.007) 0.05 to 0.09
≥ 6 97 (5.75) 57 (3.23) 1.45 (0.21) 1.10 to 2.36 0.08 (0.012) 0.06 to 0.14
Counts of risk factorsb
0 to 2 109 (6.61) 277 (15.79) 0.61 (0.20) 0.35 to 1.14 0.04 (0.01) 0.02 to 0.07
3 203 (12.31) 344 (19.61) 0.91 (0.33) 0.47 to 2.00 0.05 (0.02) 0.03 to 0.12
4 335 (20.32) 386 (22.01)c 1.22 (0.47) 0.53 to 2.62 0.07 (0.03) 0.03 to 0.15
5 346 (20.98) 377 (21.49) 1.78 (0.65) 0.67 to 3.43 0.10 (0.04) 0.04 to 0.20
6 338 (20.50) 219 (12.49) 2.44 (0.82) 0.88 to 4.33 0.14 (0.05) 0.05 to 0.25
≥ 7 318 (19.28) 151 (8.61) 3.92 (1.24) 1.11 to 7.78 0.23 (0.07) 0.06 to 0.45
a Based on the five SNPs; b Based on five SNPs and two risk factors; c Chose as ref. group.
Figure 3 Distribution of estimated absolute risk of breast cancer by modified Gail model in all samples.
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found in the Ashkenazi Jewish population [10] and was
well replicated in Europeans [41]. In the current study,
we found consistent results among Chinese; however,
no significant association was observed in other studies
involving Asian populations [17,31,36,38]. SNP
rs2046210, located at upstream of the ESR1 gene on
chromosome 6q25.1, was the only one reported by
Zheng et al. (2009) in a GWAS conducted among Chi-
nese women [14] and consistently replicated in Asian
populations (Chinese and Japanese women, including
partly overlapped samples from our group) [17,42-44]
and women of European-ancestry [14,36,37,42], but
not in African American women [31,44]. SNP
rs2981582 (10q26.13) was reported by Easton et al. in
the first large-scale breast cancer GWAS [10], which
was replicated in Europeans and Asians
[17,32-36,38,40,45-47], and was also reported pre-
viously with partly overlapped study samples by our
group [25], but not in Africans [31,46]. In the current
study, we enlarged our study subjects and obtained
similar results.
For the other SNPs, Han et al. successfully replicated
SNPs rs4973768 (3p24.1), rs889312 (5p11.2) and
rs3803662 (16q12.1) in Korean women with breast can-
cer [40]. However, SNPs rs4973768 (3q24.1), rs10941679
(5p12), rs889312 (5p11.2), rs13281615 (8q24.21),
rs3817198 (11p15.5), rs12443621 (16q12.1) and
rs6504950 (17q23.2) were not reported to be associated
with breast cancer in Chinese women [17,24,38,39],
which was similar to our results. Potential explanations
for the failure of replication of these SNPs in Chinese
could be the genetic heterogeneity (both allelic and
locus heterogeneity). Allelic heterogeneity is the phe-
nomenon in which different mutations at the same
locus (or gene) cause the same disorder. While locus
heterogeneity implies that mutation in different genes
may explain one variant phenotype. Further large scale
resequencing or fine mapping studies on these regions
may help find breast cancer causal variants.
Traditional approaches to assessing patients’ disease
risk are primarily achieved through non-genetic risk fac-
tors with apparent limitations, and it is expected that a
better prediction can be reached if we can incorporate
genetic determinants. Recently, several studies on these
efforts were published [16-22]. Zheng et al. conducted a
validation study with 3,039 breast cancer cases and
3,082 controls for 12 GWAS identified SNPs (nine
regions) in Asian women [17], and built a risk assess-
ment model with eight SNPs and five clinical risk fac-
tors. However, only five of the eight SNPs were
significantly associated with breast cancer susceptibility
in the study. In our current study, two more regions
were incorporated (3q24.1, 17q23.2) and we found five
susceptibility SNPs with a two-stage validations,
although the performance of the risk assessment model
was still limited.
Overall, risk model prediction is not a diagnostic tool
but provides an estimate of likelihood of developing dis-
ease in the future. A well-evaluated risk model, taking
genetic and clinical risk factors together, can be used as
a screening tool for high risk individuals among the gen-
eral population. Women at high risk for breast cancer
can be focused on by choosing an optimal cutoff (for
example, two-fold of the population median risk), and
these women should perform regular breast cancer
screening [48,49]. Results from this study suggest that
GWAS identified SNPs can be used to improve the pre-
diction model. However, there are a number of limita-
tions for the current study. First, several newly reported
breast cancer risk-associated SNPs were not included in
the current analysis [50]. Second, more breast cancer
associated risk factors should be evaluated, such as the
body mass index (BMI) and family history of breast can-
cer [14]. However, the effects on breast cancer risk by
BMI could not be well-evaluated in our study with a ret-
rospective study design. Our moderate study sample size
limited our power to evaluate the parameters of breast
cancer family history (only 101 cases (7.39%) and 3 con-
trols (0.29%) with a positive breast cancer family his-
tory). Third, the two-stage study design, although
helping to avoid false positive findings, may cause the
omission of low but true associations, because our over-
all study sample size is moderate.
Conclusions
Overall, five GWAS identified variants were also consis-
tently validated in this Chinese population. Risk assess-
ment models that incorporate both a genetic risk score
based on these SNPs and the established risk factors for
breast cancer may be useful for identifying high-risk
Figure 4 The area under curves (AUC) for absolute risk of
breast cancer.
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women for targeted cancer prevention. More genetic
risk variants and other risk factors should be well evalu-
ated and incorporated into the risk-predicting models to
improve the ability of personalized risk assessment.
Additional material
Additional file 1: Supplementary Figure 1. Analysis workflow.
Additional file 2: Supplementary Figure 2. Association of five SNPs
with breast cancer risk in all the study samples, stratified by estrogen
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Additional file 3: Supplementary Figure 3. Stratification analysis of
cumulative effects about the five SNPs with breast cancer risk in all
samples.
Additional file 4: Supplementary Table 1. Associations of the 15 SNPs
of breast cancer identified by previous GWAS studies and following
replicated association studies.
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